Introduction: Spinal arthrodesis is a common standard surgical procedure for spinal fusion. However, it can be associated with substantial morbidity and high pseudoarthrosis rates. Recombinant bone morphogenetic proteins (BMPs) have also been used successfully in clinical trials. However, large doses of BMPs are required to induce adequate bone repair. Hence, regional gene therapy may be a more efficient method to deliver proteins to a specific anatomic site. Adenoviruses have been the most commonly tested viral delivery vehicles in gene therapy for bone healing. However, the potential disadvantages associated with the use of adenoviral vectors in clinical situations include the lack of persistent target gene expression and pronounced host immune response to adenoviral envelope proteins in immune competent animals and humans. Recently, lentiviral vectors based on human immunodeficiency virus have been developed for gene therapy. Our previous studies demonstrated that lentiviral gene therapy allowed high levels of expression of target protein and prolonged protein production. However, lentiviral gene therapy for spinal fusion has not been compared with adenoviral gene therapy and recombinant protein therapy.
a single administration dose strategy may have a very limited duration of action and may not be ideal in certain spine fusion applications such as multilevel spine fusions and revision site is not optimal. The short-term protein production associated with adenoviral gene therapy may be better suited for these situations. In our study, RBMCs transfected with Adeno-BMP-2 induced spinal fusion and the volumes of new bone in Group II (Adeno-BMP-2) rats were greater than in Group III (rhBMP-2) rats. However, the bone masses were not abundant. Adenoviral vectors retain their ability to synthesize adenoviral proteins, which stimulate the host immune response. Host immunity destroys the transduced cells and reduces the effect of transgene expression. Interestingly, RBMCs transfected with Lenti-BMP-2 produced fusion masses that extended to adjacent levels where no fusion bed was surgically prepared. Lentiviral vectors can transfect both dividing and nondividing cells and can incorporate into the host genome; thus, these vectors have the potential for prolonged target gene expression. The strategy of prolonged expression of BMP-2 by lentiviral vector-transfected cells may be applied to induce spinal fusion, particularly in situations wherein treatment with only recombinant proteins or short-term gene therapy would be clinically inadequate. However, there are valid concerns with heterotopic bone formation and the safety of using viral vectors. For adapting lentiviral gene therapy in clinical, we have to establish an efficient regulation system of transgenic expression and dcrease risk associated with lentivirus vector, and do more animal studies to ensure the safety of lentivirus gene therapy.
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